WO2011043631A2 - Composition pharmaceutique pour la prévention et le traitement du rhume, contenant un extrait de reynoutria elliptica, une fraction de celui-ci ou un composé à base de stilbène - Google Patents

Composition pharmaceutique pour la prévention et le traitement du rhume, contenant un extrait de reynoutria elliptica, une fraction de celui-ci ou un composé à base de stilbène Download PDF

Info

Publication number
WO2011043631A2
WO2011043631A2 PCT/KR2010/006914 KR2010006914W WO2011043631A2 WO 2011043631 A2 WO2011043631 A2 WO 2011043631A2 KR 2010006914 W KR2010006914 W KR 2010006914W WO 2011043631 A2 WO2011043631 A2 WO 2011043631A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
fraction
extract
resveratrol
cold
Prior art date
Application number
PCT/KR2010/006914
Other languages
English (en)
Korean (ko)
Other versions
WO2011043631A3 (fr
Inventor
노문철
이우송
이승웅
박수진
장종선
류영배
권형준
김영민
정형재
Original Assignee
한국생명공학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국생명공학연구원 filed Critical 한국생명공학연구원
Publication of WO2011043631A2 publication Critical patent/WO2011043631A2/fr
Publication of WO2011043631A3 publication Critical patent/WO2011043631A3/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a composition for improving cold symptoms or for preventing or treating cold symptoms using as an active ingredient, e.g., root extract or fractions thereof.
  • the present invention also relates to external skin preparations, foodstuffs and personal care products containing the composition.
  • Common cold is a generic term for acute inflammatory diseases of the respiratory mucosa, such as the nose, throat, and bronchus, and includes acute rhinitis, acute pharyngitis, acute laryngitis, acute tonsillitis, bronchitis, and other viral upper respiratory tract infections.
  • the causes of the common cold are caused by various kinds of viruses, bacteria, irritation of cold and dust, imbalance of body temperature distribution and allergens, but only one of them is caused by cold and dust. It is known that the virus can be caused by a combination of stimulation and imbalance of body temperature distribution, causing a cold.
  • influenza virus There are about 50 kinds of viruses that cause colds, but the main ones are influenza virus, adenovirus, respiratory syncytial virus, rhinovirus, coxsackievirus, etc. to be.
  • the diseases caused by these viruses have a common common cold syndrome such as runny nose, sneezing, coughing, fever or sore throat, but they are collectively referred to as 'cold', but recently, the cause and symptoms are obvious with the development of medicine.
  • an independent disease such as allergic rhinitis
  • the current cold means a cold in a narrow sense, that is, a viral cold other than influenza.
  • Influenza viruses that cause pandemic influenza are classified into three types, A, B, and C, depending on the antigen type, of which A is the most common antigen mutation and accounts for 90% of the worldwide pandemic virus. .
  • These flu viruses occur worldwide every year and cause respiratory illnesses. They cause severe and painful symptoms such as chills, myalgia, lethargy, respiratory pain, headache, and abdominal pain caused by high fever. If mortality is high for children and the elderly, and complications involving bronchial diseases such as pneumonia and cardiopulmonary disease, the mortality rate is higher.
  • rhinoviruses account for 30-35% of the causes of adult colds and have more than 100 antigenic types. Infected rhinoviruses do not enter the body and survive by attaching to epithelial cells of the upper airway for 4 to 2 weeks. Unlike the flu virus, which causes pneumonia and kills infected people, rhinoviruses are known to cause runny nose, chills, headaches, and malaise, but they do not harm the body. In other words, living together while living symbiosis is easy to multiply and is known to cause acute respiratory diseases such as asthma, chronic bronchitis. Renovirus is active in early autumn, spring and summer.
  • PCR polymerase chain reaction
  • Coxsackievirus is a common infection in summer or autumn, and is known to cause viral colds along with rhinoviruses.
  • the virus was first discovered in Coxsackie, USA. It is transmitted through contaminated air, water, or feces or saliva from carriers. It is a virus that causes abnormalities in the skin, nerves, circulatory system, and respiratory system.
  • Polygonum Cuspidatum (Japanese Knotweed ) is a perennial plant of the genus Madaceae, which grows in Sanya in Korea, and is distributed in Korea, Japan, Taiwan, and China. Ho Jang-geun has been used as a diuretic, pain economy, and sedative in the private sector, and in traditional medicine in Korea and other Asian regions Has been used.
  • the present inventors while searching for a composition for the prevention and treatment of colds in natural products, resveratrol isolated from the extract or fractions thereof, or resveratrol isolated from it exhibits antiviral activity against linovirus or coxsackievirus, thereby preventing and treating colds.
  • the present invention has been completed by identifying that it can be used as a composition.
  • Another object of the present invention is to provide a cold treatment method comprising administering to a subject a composition comprising Escherichia coli extract or a fraction thereof as an active ingredient.
  • Another object of the present invention is to provide an external preparation for skin, foodstuffs and personal care products containing the composition.
  • the extracts of the present invention, the fractions thereof, and the stilbene compounds isolated therefrom exhibit excellent effects on the improvement of cold symptoms or prevention and treatment of cold symptoms caused by viruses such as rhinovirus or coxsackie virus, and thus, external skin preparations, foodstuffs It can be widely applied to cosmetics, cosmetics and personal hygiene products.
  • 1 is a diagram showing a resveratrol standard quantity curve.
  • Figure 2 is a diagram showing chromatogram and MS spectrum of Escherichia coli ethanol extract.
  • Figure 3 is a diagram showing the chromatogram and MS spectrum of E. coli ethyl acetate fraction.
  • Figure 5 is a diagram showing the chromatogram after treatment with E. coli ethanol extract and 12 hours acid.
  • FIG. 6 is a diagram showing the inhibitory activity of renovirus (HRV-2, 3, 14) of resveratrol.
  • FIG. 7 is a diagram showing renovirus (HRV2) inhibitory activity by mixing resveratrol with a virus and inoculating cells after 1 hour of reaction (before 1h) and inoculating the cells first and then adding resveratrol after 1 hour (after 1h). to be.
  • HRV2 renovirus
  • FIG. 8 shows micrographs of no vaccinated WI-38 cell lines, micrographs inoculated with each of HRV-2, HRV-3, and HRV-14, and micrographs of 100 ⁇ M of each virus and resveratrol. Is a diagram showing.
  • CVA21 cossackievirus
  • 10 to 12 are diagrams showing the inhibitory effect of inflammatory factor expression by cossackievirus (CVA21) induction of resveratrol.
  • 10 is TNF- ⁇
  • FIG. 11 is IL-6
  • FIG. 12 is a diagram showing the expression inhibitory effect of MCP-1.
  • the present invention relates to a composition for improving or preventing or treating cold symptoms, including cold root extract or fractions thereof as an active ingredient.
  • the E. coli extract is extracted with a solvent selected from the group consisting of water, a lower alcohol having 1 to 4 carbon atoms and a mixed solvent thereof, preferably methanol, ethanol or butanol.
  • the said extract shall contain the extract obtained by an extraction process, the dilution or concentrate of an extract, the dried material obtained by drying an extract, or any of these modifiers or refined products.
  • a method for obtaining Hojanggeun extract is as follows.
  • the low-strength alcohols of C 1 -C 4 to C 4 such as water, methanol, ethanol and butanol, in volume of about 2 to 20 times, preferably about 3 to 5 times, dry weight
  • the extraction temperature is 20 to 100 °C, preferably at room temperature
  • the extraction period is about 12 hours to 10 days
  • the extraction is performed using extraction methods such as hot water extraction, cold needle extraction, reflux cooling extraction, or ultrasonic extraction for 3 days to 7 days.
  • the extract is filtered 1 to 5 times by cold extraction and subjected to filtration under reduced pressure, and the filtrate is concentrated under reduced pressure at 20 to 100 ° C., preferably at room temperature using a vacuum rotary condenser, and soluble in water, lower alcohols, or a mixed solvent thereof.
  • One colic root extract can be obtained.
  • the extract of K. koji with the prophylactic and therapeutic activity of the common cold can be extracted from various organs of natural, hybrid, and mutant plants, for example roots, stems, leaves, flowers, trunks of berries, peels of berries, as well as plant tissues. Extractable from the culture and most preferably from the roots of the roots
  • the solvent fractions of the extracts of the roots of the extract may be obtained by suspending the extract of the roots of the extract with a nonpolar solvent such as n -hexane, ethyl acetate or chloroform, respectively, to obtain a polar solvent fraction and a nonpolar solvent fraction.
  • a nonpolar solvent such as n -hexane, ethyl acetate or chloroform
  • the solvent fraction is provided with water fraction, n -hexane fraction, ethyl acetate fraction or chloroform fraction.
  • a method for obtaining a fraction of the extract of Keunjangeun is as follows. Suspension of the crude extract obtained above is suspended in distilled water, and then 1 to 10 times by adding a nonpolar solvent such as hexane, ethyl acetate or chloroform in a volume of about 1 to 100 times, preferably about 1 to 5 times, the suspension. Preferably it can be obtained by extracting and separating the nonpolar solvent soluble layer in two to five times. It is also possible to further carry out conventional fractionation processes (Harborne JB Phytochemical methods: A guide to modern techniques of plant analysis, 3rd Ed. P6-7, 1998).
  • a nonpolar solvent such as hexane, ethyl acetate or chloroform
  • an equivalent amount of n-hexane and chloroform can be obtained by continuous extraction using a solvent to obtain a soluble extract of each solvent of the root extract, and more specifically, the crude extract of After suspending in water, the same amount of n-hexane was mixed and fractioned to obtain n-hexane soluble fraction and water soluble fraction, and chloroform was added to the water soluble fraction to obtain chloroform soluble fraction and water soluble fraction. can do.
  • the present invention is characterized in that the extract of Kojang-geun and its fractions contain resveratrol, a stilbene compound represented by the following formula (1).
  • Ethanol extracts and fractions of E. coli of the present invention showed high antiviral efficacy at low concentrations against various strains of rhinovirus (HRV-2, HRV-3) (Table 3).
  • extracts and fractions of K. koji muscle showed high content of resveratrol, respectively, and resveratrol showed high levels of antilinovirus and anticoxakivirus activity (FIGS. 6 to 12), and thus, containing resveratrol.
  • Knotweed extract and fractions can also be seen to be suitable for the prevention and treatment of colds.
  • the present invention relates to a composition for improving or preventing or treating cold symptoms, including resveratrol represented by Formula 1 as an active ingredient.
  • composition of the present invention includes resveratrol as an active ingredient
  • resveratrol may be used in the form of a pharmaceutically acceptable salt, and includes all salts, hydrates, and solvates prepared by conventional methods.
  • salts are acid addition salts formed with pharmaceutically acceptable free acids.
  • Acid addition salts are prepared by conventional methods, for example by dissolving a compound in an excess of aqueous acid solution and precipitating the salt using a water miscible organic solvent such as methanol, ethanol, acetone or acetonitrile. Equivalent molar amounts of the compound and acid or alcohol (eg, glycol monomethyl ether) in water can be heated and the mixture can then be evaporated to dryness or the precipitated salts can be suction filtered.
  • a water miscible organic solvent such as methanol, ethanol, acetone or acetonitrile.
  • Equivalent molar amounts of the compound and acid or alcohol (eg, glycol monomethyl ether) in water can be heated and the mixture can then be evaporated to dryness or the precipitated salts can be suction filtered.
  • organic acids and inorganic acids may be used as the free acid
  • hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, tartaric acid, and the like may be used as the inorganic acid
  • methanesulfonic acid, p -toluenesulfonic acid, acetic acid, trifluoroacetic acid, and maleic acid may be used as the organic acid.
  • maleic acid succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid (gluconic acid), galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanic acid, hydroiodic acid, and the like can be used. It is not limited.
  • Bases can also be used to make pharmaceutically acceptable metal salts.
  • Alkali metal or alkaline earth metal salts are obtained, for example, by dissolving a compound in an excess of alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the insoluble compound salt, and then evaporating and drying the filtrate.
  • the metal salt it is particularly suitable to prepare sodium, potassium or calcium salt, but is not limited thereto.
  • Corresponding silver salts may also be obtained by reacting alkali or alkaline earth metal salts with a suitable silver salt (eg, silver nitrate).
  • Pharmaceutically acceptable salts of resveratrol include salts of acidic or basic groups which may be present in the compound of resveratrol, unless otherwise indicated.
  • pharmaceutically acceptable salts may include sodium, calcium and potassium salts of the hydroxy group
  • other pharmaceutically acceptable salts of the amino group include hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, Dihydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate) and p -toluenesulfonate (tosylate) salts, and the like. It can be prepared through.
  • the term "amelioration of cold symptoms or prevention or treatment of a cold” includes the prevention and complete or partial treatment of a cold. It also includes reducing cold symptoms, ameliorating cold symptoms, alleviating the pain of a cold or its symptoms, reducing the incidence of colds, or any other change in a patient that increases treatment outcome.
  • Symptoms of a cold in which the composition of the present invention is effective are sneezing, runny nose, nasal obstruction, nasal congestion, laryngitis or sore throat, cough, sore throat, asthma and headache, fever, chills and poor condition It includes one or more of the common symptoms, such as ones that do not. Therefore, the present invention is a cough, sneezing, runny nose, myalgia, sore throat, nasal obstruction, laryngitis, sore throat, hoarseness, asthma, headache, sinus pain, rhinitis, mucosal boil, pharyngitis, bronchitis chills, chills and nausea It is effective in one or more amelioration, treatment or prevention.
  • Resveratrol of the present invention is suitable for the prevention and treatment of colds by rhinovirus, a cold virus.
  • the inhibitory effect of resveratrol on rhinovirus was measured.
  • resveratrol was mixed with a virus and inoculated into cells after 1 hour of reaction, the virus was first inoculated into cells and after 1 hour, resveratrol was added.
  • HRV2 renovirus
  • renovirus (HRV2) inhibitory activity was excellent in all cases, and thus resveratrol directly acts on the renovirus, indicating that the antiviral effect and the viral infection prevention effect are also shown (FIGS. 6 to 8). .
  • Resveratrol of the present invention is suitable for the prevention and treatment of colds by the coxsackie virus, a cold virus.
  • resveratrol was determined to inhibit the proliferation of coxsackieviruses. It was confirmed that resveratrol inhibited the proliferation of cossackie virus at significantly low concentrations (Table 4 and FIG. 9). Resveratrol was found to significantly inhibit TNF- ⁇ , IL-6 and MCP-1, which are inflammatory factors induced by coxsackievirus (Figs. 10 to 12), and resveratrol acts directly on the coxsackievirus to prevent antiviral Efficacy and virus infection prevention effects were also confirmed.
  • composition for improving or preventing or treating cold symptoms of the present invention can be used in a variety of products including foodstuffs for humans and animals, pharmaceutical products, veterinary products, cosmetics, personal care products and household products.
  • composition of the present invention can be used as an external preparation for skin, and preferably used as an external preparation for skin in the form of an ointment, lotion, spray, patch, cream, powder, suspension, gel or gel.
  • compositions of the present invention can be used in foodstuffs, preferably margarine, fat continuous or water continuous or bicontinuous spreads, fat reduced spreads, chocolate, or chocolate coating
  • confectionery such as chocolate fillings or bakery, confectionery, gum, ice cream, ice cream coatings, ice cream ingredients, dressings, mayonnaise, cheese, cream substitutes, dry soups, drinks, cereal bars, sauces, snack bars, dairy products, clinical It can be used as a nutritional or pediatric preparation.
  • composition of the present invention can be used as personal hygiene products, preferably soap, cosmetics, wet wipes, tissue paper, shampoo, mouthwash, skin cream, face cream, toothpaste, lipstick, perfume, make-up, foundation, It can be used as a ball touch, mascara, eye shadow, sunscreen lotion, hair care product, air freshener or cleansing gel.
  • E. coli extract of the present invention or a fraction thereof, or resveratrol is derived from e.g. root, a drug that has been used for a long time as a herbal, there is no problem such as toxicity and side effects.
  • the pharmaceutical composition for the prevention and treatment of colds of the present invention may comprise 0.0001 to 10% by weight, preferably 0.001 to 1% by weight of the extract and its fractions or compound 1 based on the total weight of the composition.
  • the pharmaceutical composition comprising E. coli extract, fractions thereof, or stilbene compound of the present invention may further include appropriate carriers, excipients and diluents commonly used in the preparation of pharmaceutical compositions.
  • E. coli extracts, fractions or stilbene compounds of the present invention may be used alone or in combination with other pharmaceutically active extracts, fractions or compounds as well as in a suitable collection.
  • Composition comprising the E. coli extract of the present invention, fractions or stilbene-based compounds can be treated for the cold, including administering to the subject.
  • composition comprising the extract of E. coli according to the present invention, its fractions or stilbene compounds, oral formulations, external preparations, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc. It can be formulated in the form of suppositories and sterile injectable solutions.
  • carriers, excipients, and diluents that may be included in the composition comprising the extract of K. koji, its fractions or stilbene-based compounds include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, and starch.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, in the renal vera extract, fractions thereof, or resveratrol separated therefrom.
  • Liquid preparations for oral use may include various excipients, such as wetting agents, sweeteners, fragrances, preservatives, etc., in addition to water and liquid paraffin, which are commonly used to include suspensions, solutions, emulsions, and syrups. have.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • E. coli extract, fractions thereof, or resveratrol of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration, and the duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, it is preferable to administer Escherichia coli extract or fractions of the present invention at 0.0001 to 100 mg / kg per day, preferably at 0.001 to 100 mg / kg, and resveratrol at 0.0001 to 10 mg / kg per day. As an example, it is preferable to administer at 0.001 to 10mg / kg. Administration may be administered once a day or may be divided several times.
  • the pharmaceutical composition of the present invention can be administered to various mammals such as rats, mice, livestock, humans, and the like. All modes of administration can be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.
  • the crude extract was suspended in 1 L of water and mixed with the same amount of ethyl acetate.
  • the crude extract was repeated four times to obtain 4 L of ethyl acetate fraction.
  • the ethyl acetate soluble fraction was concentrated under reduced pressure to obtain 80 g of an ethyl acetate soluble extract.
  • the chloroform: methanol 20: 1 fraction in the E. coli ethanol extract, ethyl acetate fraction, and ethyl acetate fraction column chromatography obtained above was analyzed using LC-MS to determine the resveratrol content.
  • E. coli ethyl acetate fraction was analyzed in the same manner as E. coli ethanol extract.
  • the peak of resveratrol was observed at 17 minutes, and MS analysis showed a molecular peak of m / z 227 [MH] + (FIG. 3).
  • E. coli ethanol extract (200 mg) was dissolved in 9 ml of methanol and added to 1 ml of 3M sulfuric acid solution into a round bottom flask. The flask was reacted in a 70 ° C. water bath for 12 hours and then terminated with ethyl acetate. In order to analyze the change in the content of resveratrol contained in the ethyl acetate fraction (100 mg), after preparing at 10 mg / ml concentration was injected 2 ⁇ l and analyzed using LC-MS.
  • Figure 5 shows that the area of resveratrol-3-O- ⁇ -D-glucoside peak (11 minutes) was 41,363 mAU in the ethanol extract HPLC chromatogram, but after 12 hours of acid treatment it was reduced to 26,400 mAU. Can. In addition, it can be seen that the area of the resveratrol peak (17 components) increases from 5,618 mAU to 23,380 mAU (FIG. 5).
  • the resveratrol content of K. ethanol extract was measured as 12 mg / g (ethanol extract) (Table 2), and after 12 hours of acid treatment, the resveratrol content increased about 4 times to 50 mg / g (ethanol extract).
  • methanol 20: 1 fraction on rhinovirus (HRV-2, 3) in ethanol extract, ethyl acetate fraction and ethyl acetate fraction column chromatography, The following in vitro experiments were performed using WI-38 (ATCC: CCL-75), a human lung fibroblast.
  • WI-38 cells were placed in 96 well microplates at 1 X 10 5 cells / well per well and cultured in medium EMEM (penicillin 100 units, streptomycin 100 ⁇ g, 10% FBS). When WI-38 cells became a monolayer, they were washed twice with EMEM medium containing only antibiotics. HRV-2 and HRV-3 strains were diluted to 100 TCID 50 and placed in EP tubes.
  • EMEM penicillin 100 units, streptomycin 100 ⁇ g, 10% FBS.
  • the final concentration of chloroform: methanol 20: 1 fraction in ethyl acetate and ethyl acetate fraction and ethyl acetate fraction column chromatography diluted with DMSO (dimethylsulfoxide) was 100 ⁇ g / ml, 60 ⁇ g / ml, 30 ⁇ g / mL, 10 ⁇ g / ml, 1 ⁇ g / ml was added to each tube and reacted at 4 °C for 1 hour. After 1 hour, pre-washed WI-38 cells were inoculated in 3 wells per concentration, respectively.
  • interferon alpha which is known for its antiviral effect
  • non-infected, non-administered control, and infected and non-administered control were inoculated into WI-38 cells after 1 hour of reaction under the same conditions.
  • Infected and non-administered controls were incubated for 3-4 days until complete cytopathic effect (CPE).
  • CPE cytopathic effect
  • the cells were photographed by observing the magnification of 50X daily with an inverted microscope.
  • 10 ⁇ l of Cell Counting kit-8 Dojin, Japan, tetrazolium salt WST-8) was added to each well, followed by reaction at 33 ° C. for 2 hours, and then absorbance at 450 nm. It was.
  • the rhinovirus inhibitory effect of the compound of the present invention was determined using DMSO-only cells and DMSO, HRV-2, and HRV-3 treated cells as controls.
  • the chloroform: methanol 20: 1 fractions in E. coli ethanol extract, ethyl acetate fraction and ethyl acetate fraction column chromatography were good for all strains of rhinovirus (HRV-2, HRV-3). Viral efficacy was confirmed, and it is also judged to have a direct effect on the virus and also show a virus infection prevention effect.
  • the human lung fibroblast WI-38 (ATCC: CCL-75) was used as follows. In vitro experiments were performed.
  • WI-38 cells were placed in 96 well microplates at 1 X 10 5 cells / well per well and cultured in medium EMEM (penicillin 100 units, streptomycin 100 ⁇ g, 10% FBS). When WI-38 cells became a monolayer, they were washed twice with EMEM medium containing only antibiotics.
  • HRV-2, HRV-3 and HRV-14 strains were diluted to 100 TCID 50 and placed in EP tubes. Resveratrol diluted with DMSO (dimethylsulfoxide) was added to each tube at a final concentration of 100 ⁇ M, 60 ⁇ M, 30 ⁇ M, 10 ⁇ M, 1 ⁇ M, and reacted at 4 ° C. for 1 hour. After 1 hour, pre-washed WI-38 cells were inoculated in 3 wells per concentration, respectively.
  • interferon alpha which is known for its antiviral effect
  • non-infected, non-administered control, and infected and non-administered control were inoculated into WI-38 cells after 1 hour of reaction under the same conditions.
  • Infected and non-administered controls were incubated for 3-4 days until complete cytopathic effect (CPE).
  • CPE cytopathic effect
  • the cells were photographed by observing the magnification of 50X daily with an inverted microscope.
  • 10 ⁇ l of Cell Counting kit-8 Dojin, Japan, tetrazolium salt WST-8) was added to each well, followed by reaction at 33 ° C.
  • the interferon alpha (INF- ⁇ ) used as a positive control showed a low inhibitory capacity of 22% in HRV-2, and 55.6% and 80.8% in HRV-3 and HRV-14, respectively.
  • Resveratrol of the present invention showed high inhibitory activity of 100% and 78% at 60 ⁇ M, respectively, in HRV-2 and HRV-3, and 100% inhibitory activity at 90 ⁇ M in HRV-14 strains (FIG. 6 ).
  • virus inoculation alone HRV-2, 3, 14
  • the treated group confirmed that the WI-38 cells were similar to the control group treated with nothing (FIG. 8).
  • resveratrol was able to confirm good antiviral efficacy in various strains of rhinovirus (HRV-2, HRV-3, HRV-14) of cold virus, and also acts directly on the virus to prevent viral infection. It is judged to indicate.
  • Hela H-1 cells which are human cervical cancer cells.
  • Hela-H1 cells which are human cervical cancer cells.
  • Hela-H1 cells were dispensed at 5 ⁇ 10 5 cells / well in 12 well plates and the final concentration of resveratrol was increased from 10 ⁇ M to 60 ⁇ M 1 The time was treated before. The cells were then inoculated with CVA21 of 0.01 multiplicity of infection (MOI) and infected for 1 hour. After 1 hour, uninfected CVA21 was removed by removing the supernatant, and EMEM medium to which 30 mM MgCl 2 was added was added and incubated at 37 ° C. for 24 hours.
  • MOI multiplicity of infection
  • the cultured cells were washed with PBS, washed with PBS, scraped with a scraper and collected in a tube to extract RNA using the RNeasy Mini Elute Cleanup kit. Thereafter, the inhibitory effect of inflammatory factor induction represented by resveratrol was measured in the same manner as above.
  • composition of the present invention has an antiviral effect against linovirus as well as coxsackieviruses, demonstrating that it is effective against colds caused by viral infections.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Virology (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition pharmaceutique destinée à soulager les symptômes du rhume ou à prévenir ou traiter le rhume, contenant un extrait de Reynoutria elliptica, une fraction de celui-ci ou un composé à base de stilbène dérivé de celui-ci en tant que principe actif. La présente invention concerne en outre une préparation pour la peau destinée à un usage externe, des produits alimentaires et sanitaires contenant la composition.
PCT/KR2010/006914 2009-10-08 2010-10-08 Composition pharmaceutique pour la prévention et le traitement du rhume, contenant un extrait de reynoutria elliptica, une fraction de celui-ci ou un composé à base de stilbène WO2011043631A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0095814 2009-10-08
KR1020090095814A KR101032066B1 (ko) 2009-10-08 2009-10-08 호장근 추출물, 이의 분획물 또는 스틸벤계 화합물을 포함하는 감기의 예방 및 치료용 약학 조성물

Publications (2)

Publication Number Publication Date
WO2011043631A2 true WO2011043631A2 (fr) 2011-04-14
WO2011043631A3 WO2011043631A3 (fr) 2011-11-03

Family

ID=43857306

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/006914 WO2011043631A2 (fr) 2009-10-08 2010-10-08 Composition pharmaceutique pour la prévention et le traitement du rhume, contenant un extrait de reynoutria elliptica, une fraction de celui-ci ou un composé à base de stilbène

Country Status (2)

Country Link
KR (1) KR101032066B1 (fr)
WO (1) WO2011043631A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103479777A (zh) * 2013-08-29 2014-01-01 青岛绿曼生物工程有限公司 治疗小鹅瘟的纯中药组合物及其制备方法
CN103735701A (zh) * 2014-02-10 2014-04-23 安徽科技学院 一种治疗肛门痛痒的坐浴袋泡剂
US10987008B2 (en) 2015-12-21 2021-04-27 Koninklijke Philips N.V. Device, method and computer program product for continuous monitoring of vital signs

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120133133A (ko) * 2011-05-30 2012-12-10 한국 한의학 연구원 생약 추출물 또는 이의 유산균 발효물을 포함하는 호흡기 질환의 예방 또는 치료용 조성물
KR101521010B1 (ko) * 2013-03-21 2015-05-19 강원대학교산학협력단 왕호장 추출물 및 이로부터 분리된 화합물을 유효성분으로 함유하는 인플루엔자 바이러스에 기인한 질환의 예방 및 치료용 조성물
KR102233566B1 (ko) * 2018-05-04 2021-03-30 서울대학교산학협력단 스틸벤 유도체를 포함하는 만성 폐질환의 예방 또는 치료용 조성물
KR20190045050A (ko) 2018-09-07 2019-05-02 류형준 감기 개선 식품조성물
KR20220110655A (ko) 2021-01-31 2022-08-09 (주)예스킨 코비드-19 항바이러스제 및 항바이러스제용 어주번트
KR20220110669A (ko) 2021-01-31 2022-08-09 (주)예스킨 코비드-19 항바이러스제

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950000686B1 (ko) * 1991-07-10 1995-01-27 주식회사 태평양 호장근 추출물을 함유한 미백화장료
US20070104808A1 (en) * 2001-08-06 2007-05-10 The Quigley Corporation Compositions and methods for treatment of rhinovirus
US20070154577A1 (en) * 2005-12-30 2007-07-05 Industrial Technology Research Institute Herbal compositions inhibiting free radicals
KR100824970B1 (ko) * 2006-12-26 2008-04-28 건국대학교 산학협력단 호장근 추출물 및 그의 제조방법과 알레르기 질환의치료제로서 그의 용도
KR20100058331A (ko) * 2008-11-24 2010-06-03 (주)아모레퍼시픽 호장근 추출물 또는 이로부터 분리된 레스베라트롤을 함유하는 자외선 차단용 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950000686B1 (ko) * 1991-07-10 1995-01-27 주식회사 태평양 호장근 추출물을 함유한 미백화장료
US20070104808A1 (en) * 2001-08-06 2007-05-10 The Quigley Corporation Compositions and methods for treatment of rhinovirus
US20070154577A1 (en) * 2005-12-30 2007-07-05 Industrial Technology Research Institute Herbal compositions inhibiting free radicals
KR100824970B1 (ko) * 2006-12-26 2008-04-28 건국대학교 산학협력단 호장근 추출물 및 그의 제조방법과 알레르기 질환의치료제로서 그의 용도
KR20100058331A (ko) * 2008-11-24 2010-06-03 (주)아모레퍼시픽 호장근 추출물 또는 이로부터 분리된 레스베라트롤을 함유하는 자외선 차단용 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANNA T. PALAMARA ET AL.: 'Inhibition of influenza A virus replication' JOURNAL OF INFECTIOUS DISEASES vol. 191, 15 May 2005, pages 1719 - 1729 *
CHU-HYUN LEE ET AL.: 'Neuraminidase inhibitors from Reynoutrica elliptica' ARCHIVES OF PHARMACAL RESEARCH vol. 26, no. 5, 2003, pages 367 - 374 *
LEI CHEN ET AL.: 'High-speed counter-current chromatography separation and purification of resveratrol and piceid from Polygonum cuspidatum' JOURNAL OF CHROMATOGRAPHY A vol. 907, 2001, pages 343 - 346 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103479777A (zh) * 2013-08-29 2014-01-01 青岛绿曼生物工程有限公司 治疗小鹅瘟的纯中药组合物及其制备方法
CN103735701A (zh) * 2014-02-10 2014-04-23 安徽科技学院 一种治疗肛门痛痒的坐浴袋泡剂
CN103735701B (zh) * 2014-02-10 2016-02-24 安徽科技学院 一种治疗肛门痛痒的坐浴袋泡剂
US10987008B2 (en) 2015-12-21 2021-04-27 Koninklijke Philips N.V. Device, method and computer program product for continuous monitoring of vital signs

Also Published As

Publication number Publication date
KR20110038499A (ko) 2011-04-14
WO2011043631A3 (fr) 2011-11-03
KR101032066B1 (ko) 2011-05-02

Similar Documents

Publication Publication Date Title
WO2011043631A2 (fr) Composition pharmaceutique pour la prévention et le traitement du rhume, contenant un extrait de reynoutria elliptica, une fraction de celui-ci ou un composé à base de stilbène
WO2011000150A1 (fr) Composition à visée médicale pour le traitement de la bronchite et sa préparation
KR102456294B1 (ko) 코로나바이러스 감염 예방 및 치료용 약학 조성물
WO2018128408A1 (fr) Composition pharmaceutique pour prévenir ou traiter des maladies allergiques telles que l'asthme ou l'atopie, comprenant de la baïcaléine en tant que substance active
WO2021201532A1 (fr) Composition de prévention, de soulagement ou de traitement du syndrome ménopausique chez la femme, contenant un extrait de rosa rugosa en tant que principe actif
WO2017014502A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies médiées par il-6 comprenant un extrait de fleur de rosa rugosa en tant que substance active
WO2010095858A2 (fr) Composition pharmaceutique comprenant un extrait de rhei rhizoma, des fractions de celui-ci, ou des composés à base de stilbène pour prévenir ou traiter des maladies induites par une molécule 1 d'adhésion intercellulaire.
JPH08295632A (ja) 抗菌剤
WO2016080691A1 (fr) Composition pharmaceutique comprenant des extraits de symplococs chinesis et astragalus membranaceus pour prévenir et traiter l'arthrite, et son procédé de préparation
WO2021230506A1 (fr) Composition médicinale à base d'herbes pour le traitement de la covid-19 et d'autres maladies virales
US20140030368A1 (en) Composition for preventing or treating a respiratory disease containing a mixed herbal extract of cnidium officinale root and polygoni cuspidati root
WO2023249392A1 (fr) Composition pour la prévention, l'atténuation ou le traitement d'une infection à coronavirus, contenant un extrait d'herbe médicinale utilisé en tant que principe actif
WO2023249393A1 (fr) Composition pour la prévention, l'atténuation ou le traitement d'une infection à coronavirus, contenant un extrait d'herbe médicinale utilisé en tant que principe actif
KR102551499B1 (ko) 용아초 추출물을 유효성분으로 포함하는 코로나 바이러스(SARS-CoV-2) 감염의 예방 또는 치료용 조성물
WO2022065970A2 (fr) Composition, comprenant un extrait mixte de produit naturel, pour la prévention ou le traitement d'une infection à coronavirus
WO2023008594A1 (fr) Composition pour la prévention ou le traitement d'une infection par le coronavirus (sras-cov-2), comprenant un extrait d'agrimonia pilosa en tant que principe actif
WO2017020861A1 (fr) Application d'une composition de polygonum capitatum pour résister à helicobacter pylori
WO2017020279A1 (fr) Utilisations d'une composition comprenant des racines de polygonum capitatum et de coptide dans la préparation de médicaments permettant de résister contre helicobacter pylori
WO2011019153A2 (fr) Composition pour la prévention ou le traitement de l’arthrite, contenant un extrait d’un mélange médicinal à base de plantes de schisandra chinensis baillon, scutellaria baicalensis et kalopanax pictus nakai en tant qu’ingrédient actif
WO2020122385A1 (fr) Composition comprenant un extrait d'élécampane pour soulager un symptôme de syndrome prémenstruel
WO2021045242A2 (fr) Composition d'amélioration de symptômes du syndrome prémenstruel, comprenant un extrait de chrysanthème sibiricum
WO2013154373A1 (fr) Composition comprenant des dérivés de purine ou un sel de ceux-ci pour prévenir ou traiter la dermatite atopique
WO2022220339A1 (fr) Composition pour la prévention ou le traitement d'une infection par le coronavirus (sras-cov-2), comprenant un extrait de galla rhois en tant que principe actif
WO2018021889A1 (fr) Composition contre le virus de la grippe pour membranes muqueuses
WO2019194358A1 (fr) Composition, comprenant un extrait de plante médicinale ou une fraction correspondante, destinée à la prévention ou au traitement d'une infection par le virus de la grippe

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10822276

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10822276

Country of ref document: EP

Kind code of ref document: A2